Institute For Versorgungsforschung In Der Onkologie Invo

Koblenz, Germany

Institute For Versorgungsforschung In Der Onkologie Invo

Koblenz, Germany
SEARCH FILTERS
Time filter
Source Type

Weide R.,Praxisklinik fur Hamatologie und Onkologie Koblenz | Feiten S.,Institute For Versorgungsforschung In Der Onkologie Invo | Friesenhahn V.,Institute For Versorgungsforschung In Der Onkologie Invo | Heymanns J.,Praxisklinik fur Hamatologie und Onkologie Koblenz | And 4 more authors.
Deutsche Medizinische Wochenschrift | Year: 2015

Background: Infections are major complications in chronic lymphoproliferative disorders, among them indolent non-Hodgkin's lymphoma (iNHL) including chronic lymphocytic leukemia, follicular lymphoma and multiple myeloma. We report on a retrospective cohort analysis of outpatients with indolent non-Hodgkin's lymphoma who were treated in an oncology / hematology group practice and received intravenous polyvalent immunoglobulin G (IVIG) as supportive care. The aim was to describe the treated iNHL population, the course of therapy and the effects of IVIG administrations on the levels of immunoglobulin G (IgG), the incidence of infections and the survival time. Patients and Method: 57 patients with secondary iNHL antibody deficiencies (n = 46) or IgG subclass deficiencies (n = 11) who received IVIG substitution were included. Patients received median 11 IVIG doses with a mean dose of 28 g over a period of median 9.5 months. Results: Mean IgG levels increased with IVIG substitution at about twice and then remained within the normal range. The incidence of infections decreased in 46 % of treated patients. Effects on survival could not be observed. Median overall survival was in the group of substituted patients 124 months (range 7-124), the control group had a median survival time of 96 months (range 3-129) (p = 0.537). Conclusion: IgG levels should be reviewed during IVIG substitution on a regular basis and dosage and intervals should be adjusted individually. © Georg Thieme Verlag KG Stuttgart New York.


PubMed | Institute For Versorgungsforschung In Der Onkologie Invo and Praxisklinik fur Hamatologie und Onkologie Koblenz.
Type: Journal Article | Journal: Deutsche medizinische Wochenschrift (1946) | Year: 2015

Infections are major complications in chronic lymphoproliferative disorders, among them indolent non-Hodgkins lymphoma (iNHL) including chronic lymphocytic leukemia, follicular lymphoma and multiple myeloma.We report on a retrospective cohort analysis of outpatients with indolent non-Hodgkins lymphoma who were treated in an oncology/hematology group practice and received intravenous polyvalent immunoglobulin G (IVIG) as supportive care. The aim was to describe the treated iNHL population, the course of therapy and the effects of IVIG administrations on the levels of immunoglobulin G (IgG), the incidence of infections and the survival time.57 patients with secondary iNHL antibody deficiencies (n=46) or IgG subclass deficiencies (n=11) who received IVIG substitution were included. Patients received median 11 IVIG doses with a mean dose of 28g over a period of median 9.5 months.Mean IgG levels increased with IVIG substitution at about twice and then remained within the normal range. The incidence of infections decreased in 46% of treated patients. Effects on survival could not be observed. Median overall survival was in the group of substituted patients 124 months (range 7-124), the control group had a median survival time of 96 months (range 3-129) (p=0.537).IgG levels should be reviewed during IVIG substitution on a regular basis and dosage and intervals should be adjusted individually.

Loading Institute For Versorgungsforschung In Der Onkologie Invo collaborators
Loading Institute For Versorgungsforschung In Der Onkologie Invo collaborators